Literature DB >> 24484595

Chemical constituents of Euphorbia tibetica and their biological activities.

Yang Da-Song1, He Qiu-Xia2, Yang Yong-Ping1, Liu Ke-Chun3, Li Xiao-Li4.   

Abstract

AIM: To investigate the chemical constituents and their biological activities of the aerial parts of Euphorbia tibetica.
METHOD: Compounds were isolated and purified by various chromatographic methods, and their structures were elucidated through the use of extensive spectroscopic techniques including 2D-NMR, the structures of compounds 5 and 6 were confirmed by single-crystal X-ray crystallography. Bioactivities of all the isolated compounds were evaluated by the MTT method on A549 and anti-angiogenesis assay.
RESULTS: One new compound, methyl 4-epi-shikimate-3-O-gallate (1), together with twenty-three known constituents (2-24) were isolated from the aerial parts of E. tibetica.
CONCLUSION: Compound 1 is new, and the other compounds were isolated from this plant for the first time. Compounds 5-7, 9, 11, 17, 18 and 20 exhibited inhibitory effects on the growth of human lung cancer cell A549 and compounds 5, 7, 12, 13, 17 and 19 showed anti-angiogenic effects in a zebrafish model.
Copyright © 2014 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cytotoxicity; Diterpenes; Euphorbia tibetica; Euphorbiaceae; R284.1; Shikimate derivatives

Mesh:

Substances:

Year:  2014        PMID: 24484595     DOI: 10.1016/S1875-5364(14)60007-8

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  2 in total

Review 1.  A Medicinal Halophyte Ipomoea pes-caprae (Linn.) R. Br.: A Review of Its Botany, Traditional Uses, Phytochemistry, and Bioactivity.

Authors:  Ganiyu Akinniyi; Jeonghee Lee; Hiyoung Kim; Joon-Goo Lee; Inho Yang
Journal:  Mar Drugs       Date:  2022-05-17       Impact factor: 6.085

2.  Chinese Medicine Leptochloa chinensis Inhibits the Malignant Behaviors of Renal Cell Carcinoma 786-O Cells by Regulating the mTOR Pathway.

Authors:  Yongshun Tan; Lingyun Li; Hongyue Liu; Jiadong Yu; Qijun Wang; Qiuju Lin
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-12       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.